Want to see SCNX full AI Analyst Report?
SCNX Stock Chart & Stats
$0.55
-$0.13(-2.47%)
At close: 4:00 PM EST
$0.55
-$0.13(-2.47%)
Day’s Range― - ―
52-Week Range$0.24 - $2.60
Previous CloseN/A
Volume1.53K
Average Volume (3M)4.08M
Market Cap
$18.47M
Enterprise Value$16.37
Total Cash (Recent Filing)$8.19B
Total Debt (Recent Filing)$10.69B
Price to Earnings (P/E)―
Beta2.75
Next Earnings
Nov 12, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.04
Shares Outstanding41,064,144
10 Day Avg. Volume11,411,402
30 Day Avg. Volume4,082,790
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.12
Price to Sales (P/S)181.35
P/FCF Ratio>-0.01
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$1.50Price Target Upside172.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.3
Revenue Forecast (FY)$5.12M
Bulls Say, Bears Say
Bulls Say
Strong TTM Revenue GrowthThe strong trailing-twelve-month revenue increase indicates expanding commercial activity and product adoption. If sustained, this growth can improve operating leverage and provide a broader base from which the company may approach profitability.
Commercial Launch Of RezenopyThe launch and initial wholesale orders mark a transition from development toward commercialization. Continued distribution and repeat demand could diversify revenue, validate the product strategy, and create a more durable operating platform.
Moderate Current LeverageModerate reported leverage provides some balance-sheet flexibility compared with a heavily debt-funded structure. This may help the company finance commercialization and pipeline activities without immediate reliance on substantial additional borrowing.
Bears Say
Persistent Operating LossesDeep losses across net income, EBIT, and EBITDA show that revenue growth has not yet translated into a sustainable economic model. The company must materially improve its cost structure and gross-profit conversion before growth can support durable profitability.
Severe Cash BurnLarge operating and free-cash-flow outflows indicate that the business is consuming liquidity rather than funding itself. Continued commercialization and pipeline investment may therefore require external financing, creating dilution or funding-risk pressure.
Historical Balance-sheet InstabilityAlthough current leverage is moderate, the history of major capital-structure changes reduces confidence in balance-sheet stability and comparability. Future funding needs could again alter leverage or ownership economics if cash burn remains elevated.
Scienture Holdings News
SCNX FAQ
What was Scienture Holdings’s price range in the past 12 months?
Scienture Holdings lowest stock price was $0.24 and its highest was $2.60 in the past 12 months.
What is Scienture Holdings’s market cap?
Scienture Holdings’s market cap is $18.47M.
When is Scienture Holdings’s upcoming earnings report date?
Scienture Holdings’s upcoming earnings report date is Nov 12, 2026 which is in 78 days.
How were Scienture Holdings’s earnings last quarter?
Scienture Holdings released its earnings results on Aug 14, 2026. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.09 by $0.02.
Is Scienture Holdings overvalued?
According to Wall Street analysts Scienture Holdings’s price is currently Undervalued.
Does Scienture Holdings pay dividends?
Scienture Holdings pays a Notavailable dividend of $1.5 which represents an annual dividend yield of N/A. See more information on Scienture Holdings dividends here
What is Scienture Holdings’s EPS estimate?
Scienture Holdings’s EPS estimate is -0.06.
How many shares outstanding does Scienture Holdings have?
Scienture Holdings has 41,064,144 shares outstanding.
What happened to Scienture Holdings’s price movement after its last earnings report?
Scienture Holdings reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.09. Following the earnings report the stock price went down -1.29%.
Which hedge fund is a major shareholder of Scienture Holdings?
Currently, no hedge funds are holding shares in SCNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Scienture Holdings
As a health services IT enterprise, TRxADE HEALTH, Inc. manages an online platform designed to facilitate transactions between licensed pharmaceutical wholesalers and healthcare providers. This digital marketplace enables wholesalers to distribute a broad spectrum of products and services, encompassing branded and generic drugs as well as other non-pharmaceutical items. Customers for these offerings span government organizations, hospitals, medical clinics, and independent pharmacies. The firm's corporate base is situated in Tampa, Florida.
SCNX Stock 12 Month Forecast
Average Price Target
$1.50
▲(172.73% Upside)
Technical Analysis
Ownership Overview
16.65% Insiders
1.69% Mutual Funds
<0.01% Other Institutional Investors
80.42% Public Companies and
Individual Investors